渝三峡A(000565) - 2014 Q1 - 季度财报

Financial Performance - Revenue for the first quarter was CNY 115,529,735.70, a slight increase of 0.05% compared to CNY 115,469,088.84 in the same period last year[8] - Net profit attributable to shareholders was CNY 12,074,438.02, representing a growth of 16.1% from CNY 10,400,038.21 year-on-year[8] - Basic earnings per share increased by 16.67% to CNY 0.07 from CNY 0.06 in the previous year[8] Assets and Liabilities - Total assets decreased by 6.6% to CNY 905,529,408.53 from CNY 969,477,693.98 at the end of the previous year[8] - The company reported a significant decrease in prepayments, down 30.61% to CNY 3,465,788.17[14] - Financial expenses decreased by 34.87% to CNY 2,600,881.73 due to a reduction in loan scale[15] Cash Flow - Cash flow from operating activities showed improvement, with a net outflow of CNY 8,055,264.58 compared to a net outflow of CNY 26,058,251.38 in the same period last year[8] Shareholder Information - The number of shareholders at the end of the reporting period was 23,854[11] - The total share capital of Beijing Beilu Pharmaceutical Co., Ltd. increased from 305,498,208 shares to 311,273,808 shares, with the company's shareholding remaining at 43,187,054 shares, resulting in a decrease in ownership percentage from 14.14% to 13.87%[18] Government Support and Investments - The company received government subsidies amounting to CNY 100,000.00 during the reporting period[9] - The initial investment cost in Beilu Pharmaceutical was 18,215,000.00 yuan, with a report period gain of 2,241,070.98 yuan[20] Project Development - The company’s construction in progress increased by 58.10% to CNY 7,504,193.36, reflecting ongoing project developments[14] Brand Recognition - The company obtained the title of "China Famous Trademark" on March 21, 2014[19]